论文部分内容阅读
抗人膀胱癌单克隆抗体ＢＤＩ－１通过２－巯基乙醇直接还原法标记得－９９ｍ制备了９９ｍＴｃ－ＢＤＩ－１。质量控制实验结果表明，标记率为６９．９％，分离纯化后标记抗体的放化纯度高于９０％。标记抗体的免疫活性分数为８１％，亲和常数为１．２２ｘ１０９Ｍ－１。本文在上述结果基础上，研究了标记抗体在荷人膀胱癌裸鼠体内的分布及放射免疫显像。９９ｍＴｃ－ＢＤＩ－１经尾静脉注射后，分别在４，１６及２２小时γ照相后断颈处死小鼠，取脏器称湿重并计数。９９ｍＴｃ－ＢＤＩ－１注射后２２小时肿瘤清晰显示，肿瘤对标记抗体的吸收率为２０．７％ＩＤ／ｇ：平均Ｔ／ＮＴ为１０．５２，最小Ｔ／ＮＴ为２．９０（肿瘤／肾脏）；最大Ｔ／ＮＴ为２０．７（肿瘤／小肠或肌）。上述研究结果为进一步临床应用奠定基础。
99mTc-BDI-1 was prepared by anti-human bladder cancer monoclonal antibody BDI-1 labeled with -99m by 2-mercaptoethanol direct reduction method. The results of quality control experiments showed that the labeling efficiency was 69.9%, and the radiochemical purity of the labeled antibody was higher than 90% after isolation and purification. The labeled antibody had an immunocompetent fraction of 81% and an affinity constant of 1.22 × 109 M-1. Based on the above results, we studied the distribution and radioimmunoimaging of labeled antibody in human bladder cancer nude mice. After injection of 99mTc-BDI-1 via the caudal vein, mice were sacrificed at 4, 16 and 22 hours after gamma photography, respectively. The organs were weighed and wet-weighted. At 22 hours after injection of 99mTc-BDI-1, tumors clearly showed a 20.7% ID / g absorbance of the labeled antibody for the tumor: an average T / NT of 10.52 and a minimum T / NT of 2.90 (tumor / kidney ); Maximum T / NT was 20.7 (tumor / small intestine or muscle). The above findings lay the foundation for further clinical application.